Imbed’s Microlyte Matrix Added to VA’s IDIQ Contract

MADISON, Wis.–(BUSINESS WIRE)–Imbed Biosciences Inc. (Imbed), a developer of next-generation therapies for tissue repair, and Spartan Medical, a veteran-owned federal contractor with fourteen years of steadfast performance, jointly announced today that Imbed’s Microlyte® Matrix dressing portfolio has been added to Spartan Medical’s VA IDIQ contract with the US Department of Veterans Affairs (VA). The IDIQ contract, which stands for Indefinite Delivery and Indefinite Quantity, will streamline the procurement process in VA hospital systems and expedite the delivery of products to the care of our nation’s heroes. Under this contract, any VA hospital can order as many quantities of Microlyte® Matrix, and as many times as needed, while complying with and operating under the preferred contract vehicle within the VHA.

“The Microlyte® Matrix portfolio is approved by VA’s Strategic Acquisition Center (SAC) under our National VA IDIQ Contract #36C10G18D0143, staying true to our philosophy of providing the best care to those who deserve it the most. The approval makes this innovative technology readily available for ordering by any clinician or administrator at any VA facility nationwide,” said Vince Proffitt, president and CEO of Spartan Medical.

The Veterans Health Administration (VHA) is the largest integrated health care system in the United States, providing care at nearly 1,300 health care facilities to more than 9 million veterans enrolled in the VA health care program.

“We are proud to partner with Spartan Medical to bring this latest innovation in VA wound management to serve our veterans. The IDIQ contract gives Microlyte Matrix a rare opportunity to gain access to the entire VHA integrated healthcare system, leaving no veteran behind,” said Ankit Agarwal, PhD, President and CEO of Imbed.

“In published clinical studies, the antimicrobial microlyte matrix has been shown to accelerate healing of chronic blocked wounds and also reduce the incidence of surgical site infections in high-risk patients,” said Dr. Michael Schurr, MD. , co-founder. d’Imbed and critical care surgeon at Mission Hospital in Asheville, North Carolina. “The effectiveness of Microlyte® Matrix has been associated with its ultra-thin, multi-layered architecture that intimately conforms to the underlying wound surface, provides a template for tissue growth, and kills bacteria on contact hidden in crevices. These studies recommend considering Microlyte® Matrix as the primary antimicrobial dressing in standard care protocols for complex wounds.It could significantly improve healing of chronic and surgical wounds, and thus reduce the use of antibiotics and opioids, which that would save the government billions of dollars in healthcare costs.

About Imbed Biosciences, Inc.

Imbed is a private, growth-stage biotechnology company registered with the FDA as a medical device manufacturer with an ISO 13485 certified quality management system. The company has a portfolio of products in market and in development based on its patented Microlyte® Matrix technology to fight pain and local infections in complex wounds such as burns, surgery and diabetic foot ulcers. Research at Imbed is funded in part by the National Institutes of Health, the US Army, and the US Navy. For more information, visit and

About Spartan Medical

Spartan Medical Inc. was founded in 2008 by a former Air Force intelligence officer to provide an extensive portfolio of leading-edge partner medical devices and technologies focused on the needs of VA and DoD surgeons. Spartan Medical is considered a priority supplier in VA as a CVE Certified Disabled Veteran-Owned Small Business (SDVOSB), and has been awarded more than 700 federal government contracts, including multi-year general purchase agreements in more of 30 major military processing facilities. with over 14 years of flawless performance.

About Florence L. Silvia

Check Also

Risks to shareholder returns are high at these prices for Golden Matrix Group, Inc. (NASDAQ: GMGI)

Golden Matrix Group, Inc. (NASDAQ:GMGI) a price/earnings ratio (or “P/E”) of 58.5x could give the …